Lung Cancer: Diagnosis and Management (NICE NG122)

NICE NG122 covers the diagnosis, staging, and treatment of lung cancer including NSCLC and SCLC, with guidance on targeted therapy and immunotherapy.

Key Recommendations

• Urgent CT chest for suspected lung cancer (2-week wait referral)
• PET-CT for staging if curative treatment being considered
• EGFR mutation testing for all non-squamous NSCLC
• ALK, ROS1, BRAF, MET, RET, KRAS G12C, and PD-L1 testing for appropriate cases
• EGFR TKI (osimertinib) first-line for EGFR-mutant advanced NSCLC
• PD-L1 ≥50%: pembrolizumab first-line monotherapy
• Refer to thoracic MDT for all suspected lung cancer cases